Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Reproductive Solutions’ Diana Peninger Shares Insights on ProteX, a Solution for Male Infertility
VIEWPOINTS

PharmaShots Interview: Reproductive Solutions’ Diana Peninger Shares Insights on ProteX, a Solution for Male Infertility

In an interview with PharmaShots, Diana Peninger, President and CEO at Reproductive Solutions shares her views on the ProteX sperm collection solution, offering a new hope for infertile couples. Shots: Reproductive Solutions (RSI) reported the availability of a patented, FDA-listed semen collection container that improves specimen quality for in vitro fertilization and other assisted reproductive technologies The ProteX container…
April 18, 2022

Read more

Viewpoints_Suela Sulo
VIEWPOINTS

PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care

In an interview with PharmaShots, Suela Sulo, Ph.D., M.S., Director of Global Health Economics, Outcomes Research and Policy at Abbott shared her views on how this study will shift the way to approach nutrition across the continuum of care. Shots: A study published in the Journal of Primary Care and Community Health has shown that a new…
October 13, 2021

Read more

Viewpoints_Dr. Ramon Mohanlal
VIEWPOINTS

PharmaShots Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021

In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC. Shots: Plinabulin in combination with nivolumab and ipilimumab showed 46% ORR with one…
July 12, 2021

Read more

Insights+ Key Biosimilars Events of June 2021
INSIGHTS+

Insights+ Key Biosimilars Events of June 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Jun, Celltrion launched Remsima SC (biosimilar, infliximab) for…
June 30, 2021

Read more

Viewpoints_Nathalie Landry
VIEWPOINTS

PharmaShots Interview: Medicago’s Nathalie Landry Shares Insights on the Phase 2 Results of Plant-Based COVID-19 Vaccine

In an Interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific, and Medical Affairs at Medicago share her views on the P-II results of adjuvanted plant-based COVID-19 vaccine. Shots: The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged =18yrs. with two age groups (18-64yrs & over 65yrs.) across…
June 29, 2021

Read more

Load more